ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "complement"

  • Abstract Number: 2065 • ACR Convergence 2024

    Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)

    Samantha Coss1, Danlei Zhou1, Rabheh Abdul Aziz2, Katherine Miller3, Shoghik Akoghlanian4, Kyla Driest1, Edward Oberle1, Vidya Sivaraman5, Charles Spencer6, Stacy Ardoin1 and Chack-Yung Yu7, 1Nationwide Children's Hospital, Columbus, OH, 2University at Buffalo, Buffalo, NY, 3Nationwide Children's Hospital, Institute for Genomic Medicine, Columbus, OH, 4Nationwide Children�s Hospital, Columbus, OH, 5Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 6University of Mississippi Medical Center, Jackson, MS, 7Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, OH

    Background/Purpose: JDM is an autoimmune disease of skin and muscle. We investigated genetic factors, autoantibodies, and clinical features in JDM.Methods: Subjects came from 2 large…
  • Abstract Number: 0040 • ACR Convergence 2024

    Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis

    Gary Sims1, Mia Collins2, Natalie Pursell3, Teneema Kuriakose1, Fanyi Jiang4, Kristi Moore5, Lucie Bertrand5, Melissa Lasaro5, Jessica Neisen6, Scott Manetz7, Gabriel Wong8, Patrick Riley5, Iain McInnes9, Kyriakos Konstantinidis10 and David Close8, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 3Dicerna, Lexington, 4Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 5Alexion, AstraZeneca Rare Disease, New Haven, CT, 6Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 7Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 8Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 9University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 10Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
  • Abstract Number: 2177 • ACR Convergence 2024

    CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients

    Dror Mevorach, Netanel Karbian, Marian Zeibak and Adi Tabib, Hadassah-University Hospital, Jerusalem, Israel

    Background/Purpose: We have described in 2013, homozygous CD59-deficient children that manifest with recurrent peripheral neuropathy resembling Guillain-Barré syndrome (GBS), with hemolytic anemia and recurrent strokes.…
  • Abstract Number: 0045 • ACR Convergence 2024

    Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins

    Khushali Trivedi1, Clarissa Klenke2, Jun Kim1, Jeba Atkia Maisha2, Alina Sememenko1, XIAOBO MENG2, Mario Navarrete1, Hani El-Gabalawy2 and Liam O'Neil2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
  • Abstract Number: 2230 • ACR Convergence 2024

    Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis

    Maria Garcia-Gonzalez1, Fuensanta Gomez-Bernal2, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
  • Abstract Number: 0114 • ACR Convergence 2024

    Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cécile Yelnik1, shruti chaturvedi2, Julien Labreuche3, Xiang-Zuo Pan2, H Michael Belmont4, Nina Kello5, Paul Fortin6, David Branch7, Yu Zuo8, Rohan Willis9, Robert Brodsky2, Jane Salmon10, Maria Laura Bertolaccini11, Hannah Cohen12, Michelle Petri13 and Doruk Erkan10, and on behalf of APS ACTION, 1lille university, Lille, France, 2John Hopkins University, Baltimore, MD, 3Lille University Hospital, Lille, France, 4NYU Langone Health, New York, NY, 5Northwell Health, Brooklyn, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7University of Utah and Intermountain Healthcare, Salt Lake City, UT, 8University of Michigan, Ann Arbor, MI, 9University of Texas Medical Branch, Galveston, TX, 10Hospital for Special Surgery, New York, NY, 11King's College London, London, United Kingdom, 12University College London Hospitals NHS Foundation Trust, London, United Kingdom, 13Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: We previously reported that markers of complement activation, specifically elevated C4d levels and positive modified HAM (mHAM) test, are associated with a higher risk…
  • Abstract Number: 2401 • ACR Convergence 2024

    A Novel Modeling Approach to Elucidate the Role of Autoantibodies in Complement Activation in SLE

    David Pisetsky1, Yuankang Zhao2, Matthew Engelhard3, Amanda Eudy4, Philip Tedeschi5, Alex Verdone5, Megan Clowse6, Lisa Criscione-Schreiber2, Jayanth Doss3, Mithu Maheswaranathan2, Rebecca Sadun3, Kai Sun3 and Jennifer Rogers2, 1Duke University Medical Center, Durham, NC, 2Duke University, Durham, 3Duke University, Durham, NC, 4Duke University, Raleigh, NC, 5Immunovant, Inc, New York, NY, 6Duke University, Chapel Hill, NC

    Background/Purpose: In SLE, ANAs can promote pathogenesis by forming immune complexes (ICs) that activate complement.  While antibodies to DNA (anti-DNA) are known to be associated…
  • Abstract Number: 0298 • ACR Convergence 2024

    RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults

    Miwa Haranaka1, Akinori Yamada2, Saki Takahashi2, Keisuke Gotanda2, Sonoko Nakano-Kanatani2, Nana Uemura2, Kensuke Ohnishi2, Masanobu Nishidate2, Ichio Ohnami2 and Megumi Kai3, 1Souseikai Hakata Clinic, Fukuoka, Japan, 2Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 3Oita University, Oita, Japan

    Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
  • Abstract Number: 2478 • ACR Convergence 2024

    Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

    Christian Pagnoux1, Antoine Neel2, Sarah Bray3, Rachel E. Gurlin4, Darcy Trimpe5, David Jayne6 and Peter Merkel7, and ADVOCATE Study Group, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Department of Internal Medicine, CHU Nantes, Nantes, France, 3Amgen Ltd, Cambridge, United Kingdom, 4Amgen Inc., Mountain View, CA, 5Amgen Inc., Thousand Oaks, CA, 6University of Cambridge, Cambridge, United Kingdom, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
  • Abstract Number: 0461 • ACR Convergence 2024

    Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis

    ivan Ferraz-Amaro1, Maria Garcia-Gonzalez2, Fuensanta Gomez-Bernal3, Juan Carlos Quevedo-Abeledo4 and Miguel Angel Gonzalez-Gay5, 1Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 3Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 4Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 5University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain

    Background/Purpose: The complement (C) system has been implicated in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to examine the correlation between an in-depth evaluation…
  • Abstract Number: 2480 • ACR Convergence 2024

    Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial

    Robert Spiera1, Robert Lebovics2, Sarah Bray3, Rachel E. Gurlin4, David Jayne5 and Peter Merkel6, and ADVOCATE Study Group, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2Hackensack Meridian University Health System, Hackensack, NJ, 3Amgen Ltd, Cambridge, United Kingdom, 4Amgen Inc., Mountain View, CA, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…
  • Abstract Number: 0471 • ACR Convergence 2024

    Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis

    Jose Viotti-Serra1, Maria Garcia-Gonzalez2, Fuensanta Gomez-Bernal1, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
  • Abstract Number: 2483 • ACR Convergence 2024

    Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study

    Yusuke Ushio1, Hiromi Shimada2, taichi miyagi3, Koichi Sugihara4, Mao Mizusaki5, Rina Mino5, Hayamasa yamaguchi5, Naoto Manabe5, Shusaku Nakashima2 and Hiroaki Dobashi2, 1Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 2Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, 4Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, 5Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan

    Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was demonstrated to be an alternative to glucocorticoids (GC) in the treatment of microscopic polyangiitis (MPA)/granulomatosis with polyangiitis…
  • Abstract Number: 0497 • ACR Convergence 2024

    Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis

    Adrián Quevedo-Rodríguez1, Marta Hernández-Díaz2, Dara Rodríguez-González22, Fuensanta Gomez-Bernal3, Juan Carlos Quevedo-Abeledo4, Agustín F González-Rivero2, Elena González López5, gonzalo Ocejo-Viñals5, Miguel Angel Gonzalez-Gay6 and ivan Ferraz-Amaro7, 1Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 2Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, 3Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 4Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 5Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 6University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 7Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
  • Abstract Number: 2488 • ACR Convergence 2024

    Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis

    Sushmitha Inguva1, Pallavi Rane1, Darcy Trimpe1, Sam Oh1, Jasjit Multani2, Hsiu-Ching Chang2, Marie Yasuda2, Chi-Chang Chen2, Duvuru Geetha3, Peter Merkel4 and Zachary Wallace5, 1Amgen Inc., Thousand Oaks, CA, 2IQVIA, Wayne, PA, 3Johns Hopkins University, Baltimore, MD, 4University of Pennsylvania, Philadelphia, PA, 5Massachusetts General Hospital, Newton, MA

    Background/Purpose: The United States (US) Food and Drug Administration approved avacopan to treat adults with severe active granulomatosis with polyangiitis or microscopic polyangiitis in October…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology